- Home
- EVO vs OCUL Comparison
EVO vs OCUL Comparison
Compare EVO & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVO
- OCUL
- Stock Information
- Founded
- EVO 1993
- OCUL 2006
- Country
- EVO Germany
- OCUL United States
- Employees
- EVO N/A
- OCUL N/A
- Industry
- EVO Biotechnology: Pharmaceutical Preparations
- OCUL Biotechnology: Pharmaceutical Preparations
- Sector
- EVO Health Care
- OCUL Health Care
- Exchange
- EVO Nasdaq
- OCUL Nasdaq
- Market Cap
- EVO 1.4B
- OCUL 1.4B
- IPO Year
- EVO 2021
- OCUL 2014
- Fundamental
- Price
- EVO $3.76
- OCUL $8.13
- Analyst Decision
- EVO Buy
- OCUL Strong Buy
- Analyst Count
- EVO 2
- OCUL 10
- Target Price
- EVO $5.90
- OCUL $16.11
- AVG Volume (30 Days)
- EVO 159.9K
- OCUL 2.5M
- Earning Date
- EVO 08-13-2025
- OCUL 08-06-2025
- Dividend Yield
- EVO N/A
- OCUL N/A
- EPS Growth
- EVO N/A
- OCUL N/A
- EPS
- EVO N/A
- OCUL N/A
- Revenue
- EVO $851,944,444.00
- OCUL $59,647,000.00
- Revenue This Year
- EVO $10.08
- OCUL N/A
- Revenue Next Year
- EVO $10.99
- OCUL $20.05
- P/E Ratio
- EVO N/A
- OCUL N/A
- Revenue Growth
- EVO 1.50
- OCUL N/A
- 52 Week Low
- EVO $2.84
- OCUL $5.79
- 52 Week High
- EVO $5.64
- OCUL $11.78
- Technical
- Relative Strength Index (RSI)
- EVO 41.37
- OCUL 48.84
- Support Level
- EVO $4.06
- OCUL $8.44
- Resistance Level
- EVO $4.44
- OCUL $9.41
- Average True Range (ATR)
- EVO 0.11
- OCUL 0.47
- MACD
- EVO -0.04
- OCUL -0.06
- Stochastic Oscillator
- EVO 0.00
- OCUL 17.42
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.